Vicor (VICR) Stock Forecast & Price Target

Vicor is supported by a compelling combination of accelerating royalty monetization and structural demand in high-growth compute markets, as evidenced by the 9/21 raise to >20% sequential 3Q26 revenue growth after a new VPD licensing agreement with a leading AI OEM and the expectation of about $35.0M in Q3 royalty revenue versus $20.0M previously. The business is also showing operational leverage and improving underlying fundamentals, with 2Q26 revenue of $143.4M up 26.9% sequentially and 1.6% year over year, non-GAAP gross margin of 58.6%, non-GAAP EPS of $1.13, and backlog rising 26% sequentially to $379.7M, while strength in Advanced Products, high-performance compute, industrial, ATE, and aerospace and defense indicates broad demand breadth. Longer-term conviction is reinforced by the company’s patented Factorized Power Architecture, its expanding licensing ecosystem with the fourth agreement secured with a hyperscaler or AI OEM, and capacity expansion via secured Fab-2 and Fab-3 sites, all of which support additional revenue scaling as management pursues higher manufacturing capacity and continued adoption of vertical power delivery technology.

Vicor is viewed negatively because its upside is constrained by governance risk, with the Chairman & CEO controlling nearly 80% of the voting stock and therefore able to shape corporate policies that may disadvantage minority shareholders. Although the company has differentiated technology in ChiP and FPA and management raised FY26 revenue guidance to more than $600 million, the outlook is tempered by heavy dependence on advanced product adoption, conservative licensing assumptions, and an ongoing patent-enforcement strategy that includes three additional infringement lawsuits on September 8, 2026. The business may also face valuation and execution pressure as the market has seen multiple compression across AI semiconductor stocks, while 3Q26 revenue is only expected to rise 10% sequentially to about $158 million despite a strong 2Q26 book-to-bill of roughly 1.7 and backlog of $380 million.